From protein interaction networks to novel therapeutic strategies

IUBMB Life

Volumn 64, Issue 6, 2012, Pages 529-537

  Jaeger, Samira ^a   Aloy, Patrick ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

drug cocktails; drug repositioning; network medicine; polypharmacology; protein networks

Indexed keywords

AFATINIB; ARF PROTEIN; BACLOFEN; BCR ABL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; COTININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEMOGLOBIN BETA CHAIN; INTERSTITIAL COLLAGENASE; LAPATINIB; MASPIN; MILTEFOSINE; MRE11 PROTEIN; NALTREXONE; NERATINIB; PERTUZUMAB; PROTEIN BAX; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; SOMATOMEDIN RECEPTOR; SORBITOL; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BREAST CANCER; CELL CYCLE ARREST; CLINICAL EFFECTIVENESS; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG REPOSITIONING; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LEISHMANIASIS; LEPROSY; LUNG METASTASIS; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NAUSEA; ONCOGENE; PHENOTYPE; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; SAFETY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEINS;

EID: 84861310336     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1040     Document Type: Review

References (83)

1. Metzker, M. L., (2010) Sequencing technologies-the next generation. Nat. Rev. Genet. 11, 31-46.
2. Schloss, P. D., and, Handelsman, J., (2005) Metagenomics for studying unculturable microorganisms: cutting the Gordian knot. Genome Biol. 6, 229.
3. Stein, L., (2001) Genome annotation: from sequence to biology. Nat. Rev. Genet. 2, 493-503.
4. Eisenberg, D., Marcotte, E. M., Xenarios, I., and, Yeates, T. O., (2000) Protein function in the post-genomic era. Nature 405, 823-826.
5. Frishman, D., (2007) Protein annotation at genomic scale: the current status. Chem. Rev. 107, 3448-3466.
6. Whisstock, J. C., and, Lesk, A. M., (2003) Prediction of protein function from protein sequence and structure. Q. Rev. Biophys. 36, 307-340.
7. Mendel, G., (1866) Versuche über Pflanzenhybriden. Verhandlungen des naturforschenden Vereines in Brünn, Bd. IV für das Jahr 1865, Abhandlungen. pp. 3-47.
8. Morgan, T. H., (1910) Sex limited inheritance in drosophila. Science 32, 120-122.
9. Barabási, A. L., Gulbahce, N., and, Loscalzo, J., (2011) Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68.
10. Vogelstein, B., Lane, D., and, Levine, A. J., (2000) Surfing the p53 network. Nature 408, 307-310.
11. Hollstein, M., Sidransky, D., Vogelstein, B., and, Harris, C. C., (1991) p53 mutations in human cancers. Science 253, 49-53.
12. Blagosklonny, M. V., (2002) P53: an ubiquitous target of anticancer drugs. Int. J. Cancer 98, 161-166.
13. Hainaut, P., and, Wiman, K. G., (2009) 30 years and a long way into p53 research. Lancet Oncol. 10, 913-919.
14. Levine, A. J., and, Oren, M., (2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758.
15. Vousden, K. H., and, Lane, D. P., (2007) p53 in health and disease. Nat. Rev. Mol. Cell. Biol. 8, 275-283.
16. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., and, Lane, D. P., (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862-873.
17. Barabási, A. L., and, Oltvai, Z. N., (2004) Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5, 101-113.
18. Piehler, J., (2005) New methodologies for measuring protein interactions in vivo and in vitro. Curr. Opin. Struct. Biol. 15, 4-14.
19. Berggard, T., Linse, S., and, James, P., (2007) Methods for the detection and analysis of protein-protein interactions. Proteomics 7, 2833-2842.
20. Shoemaker, B. A., and, Panchenko, A. R., (2007) Deciphering protein-protein interactions. I. Experimental techniques and databases. PLoS Comput. Biol. 3, e42.
21. Finley, R. L. Jr., and, R. Brent, (1994) Interaction mating reveals binary and ternary connections between Drosophila cell cycle regulators. Proc. Natl. Acad. Sci. USA 91, 12980-12984.
22. Goehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., et al. (2004) A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 15, 853-865.
23. Mayes, A. E., Verdone, L., Legrain, P., and, Beggs, J. D., (1999) Characterization of Sm-like proteins in yeast and their association with U6 snRNA. EMBO J. 18, 4321-4331.
24. Fields, S., and, Song, O., (1989) A novel genetic system to detect protein-protein interactions. Nature 340, 245-246.
25. Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., et al. (1999) A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17, 1030-1032.
26. Yu, H., Braun, P., Yildirim, M. A., Lemmens, I., Venkatesan, K., et al. (2008) High-quality binary protein interaction map of the yeast interactome network. Science 322, 104-110.
27. De Las Rivas, J., and, Fontanillo, C., (2010) Protein-protein interactions essentials: key concepts to building and analyzing interactome networks. PLoS Comput. Biol. 6, e1000807.
28. Yook, S. H., Oltvai, Z. N., and, Barabasi, A. L., (2004) Functional and topological characterization of protein interaction networks. Proteomics 4, 928-942.
29. Sharan, R., Ulitsky, I., and, Shamir, R., (2007) Network-based prediction of protein function. Mol. Syst. Biol. 3, 88.
30. Dittrich, M. T., Klau, G. W., Rosenwald, A., Dandekar, T., and, Muller, T., (2008) Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics 24, i223-i231.
31. Spirin, V., and, Mirny, L. A., (2003) Protein complexes and functional modules in molecular networks. Proc. Natl. Acad. Sci. USA 100, 12123-12128.
32. Jaeger, S., Sers, C. T., and, Leser, U., (2010) Combining modularity, conservation, and interactions of proteins significantly increases precision and coverage of protein function prediction. BMC Genomics 11, 717.
33. Sharan, R., Suthram, S., Kelley, R. M., Kuhn, T., McCuine, S., et al. (2005) Conserved patterns of protein interaction in multiple species. Proc. Natl. Acad. Sci. USA 102, 1974-1979.
34. Goh, K. I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., et al. (2007) The human disease network. Proc. Natl. Acad. Sci. USA 104, 8685-8690.
35. Ideker, T., and, Sharan, R., (2008) Protein networks in disease. Genome Res. 18, 644-652.
36. Berger, S. I., and, Iyengar, R., (2009) Network analyses in systems pharmacology. Bioinformatics 25, 2466-2472.
37. Pujol, A., Mosca, R., Farres, J., and, Aloy, P., (2010) Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci. 31, 115-123.
38. Tong, A. H., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., et al. (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294, 2364-2368.
39. Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437.
40. Bandyopadhyay, S., Chiang, C. Y., Srivastava, J., Gersten, M., White, S., et al. (2010) A human MAP kinase interactome. Nat. Methods 7, 801-805.
41. Hannum, G., Srivas, R., Guenole, A., van Attikum, H., Krogan, N. J., et al. (2009) Genome-wide association data reveal a global map of genetic interactions among protein complexes. PLoS Genet. 5, e1000782.
42. Dipple, K. M., and, McCabe, E. R., (2000) Modifier genes convert "simple" Mendelian disorders to complex traits. Mol. Genet. Metab. 71, 43-50.
43. Driss, A., Asare, K. O., Hibbert, J. M., Gee, B. E., Adamkiewicz, T. V., et al. (2009) Sickle cell disease in the post genomic era: a monogenic disease with a polygenic phenotype. Genomics Insights 2009, 23-48.
44. Aerts, S., Lambrechts, D., Maity, S., Van Loo, P., Coessens, B., et al. (2006) Gene prioritization through genomic data fusion. Nat. Biotechnol. 24, 537-544.
45. Turner, F. S., Clutterbuck, D. R., and, Semple, C. A., (2003) POCUS: mining genomic sequence annotation to predict disease genes. Genome Biol. 4, R75.
46. Schuster-Bockler, B., and, Bateman, A., (2008) Protein interactions in human genetic diseases. Genome Biol. 9, R9.
47. Wong, J. M., Ionescu, D., and, Ingles, C. J., (2003) Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2. Oncogene 22, 28-33.
48. Jonsson, P. F., and, Bates P. A., (2006) Global topological features of cancer proteins in the human interactome. Bioinformatics 22, 2291-2297.
49. Soler-Lopez, M., Zanzoni, A., Lluis, R., Stelzl, U., and, Aloy, P., (2011) Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res. 21, 364-376.
50. Gandhi, T. K., Zhong, J., Mathivanan, S., Karthick, L., Chandrika, K. N., et al. (2006) Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat. Genet. 38, 285-293.
51. Xu, J., and, Li, Y., (2006) Discovering disease-genes by topological features in human protein-protein interaction network. Bioinformatics 22, 2800-2805.
52. Brunner, H. G., and, van Driel, M. A., (2004) From syndrome families to functional genomics. Nat. Rev. Genet. 5, 545-551.
53. Kaltenbach, L. S., Romero, E., Becklin, R. R., Chettier, R., Bell, R., et al. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3, e82.
54. Perreau, V. M., Orchard, S., Adlard, P. A., Bellingham, S. A., Cappai, R., et al. (2010) A domain level interaction network of amyloid precursor protein and Abeta of Alzheimer's disease. Proteomics 10, 2377-2395.
55. Taylor, I. W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204.
56. Tranchevent, L. C., Capdevila, F. B., Nitsch, D., De Moor, B., De Causmaecker, P., et al. (2011) A guide to web tools to prioritize candidate genes. Brief Bioinform. 12, 22-32.
57. Oti, M., Snel, B., Huynen, M. A., and, Brunner, H. G., (2006) Predicting disease genes using protein-protein interactions. J. Med. Genet. 43, 691-698.
58. Kohler, S., Bauer, S., Horn, D., and, Robinson, P. N., (2008) Walking the interactome for prioritization of candidate disease genes. Am. J. Hum. Genet. 82, 949-958.
59. Lage, K., Karlberg, E. O., Storling, Z. M., Olason, P. I., Pedersen, A. G., et al. (2007) A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol. 25, 309-316.
60. Arrowsmith, J., (2011) Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87.
61. Arrowsmith, J., (2011) Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329.
62. Hopkins, A. L., (2008) Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690.
63. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L., and, Vidal, M., (2007) Drug-target network. Nat. Biotechnol. 25, 1119-1126.
64. Booth, B., and, Zemmel, R., (2003) Quest for the best. Nat. Rev. Drug Discov. 2, 838-841.
65. Major, E. O., (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47.
66. Pache, R. A., Zanzoni, A., Naval, J., Mas, J. M., and, Aloy, P., (2008) Towards a molecular characterisation of pathological pathways. FEBS Lett. 582,. 1259-1265.
67. Hwang, W. C., Zhang, A., and, Ramanathan, M., (2008) Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin. Pharmacol. Ther. 84, 563-572.
68. Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., et al. (2009) Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106, 7414-7419.
69. Burkard, T. R., Rix, U., Breitwieser, F. P., Superti-Furga, G., and, Colinge, J., (2010) A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput. Biol. 6, e1001001.
70. Ashburn, T. T., and, Thor, K. B., (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673-683.
71. DiMasi, J. A., Hansen, R. W., and, Grabowski, H. G., (2003) The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185.
72. von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., et al. (2011) PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 39, D1060-D1066.
73. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J., and, Bork, P., (2008) Drug target identification using side-effect similarity. Science 321, 263-266.
74. Kuhn, M., Campillos, J. M., Bork, P., Jensen, L. J., Gavin, A. C., et al. (2008) Use of aprepitant and derivatives thereof for the treatment of cancer. Patent WO 2009/124756 A1; CT/EP2009/002621.
75. Duran-Frigola, M., and, Aloy, P., (2012) Recycling side-effects into clinical markers for drug repositioning. Genome Med. 4, 3.
76. Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347, 1739-1746.
77. Rajkumar, S. V., (2004) Thalidomide: tragic past and promising future. Mayo Clin. Proc. 79, 899-903.
78. Keith, C. T., Borisy, A. A., and, Stockwell, B. R., (2005) Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78.
79. Jia, J., Zhu, F., Ma, X., Cao, Z., Li, Y., et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128.
80. Tsang, R. Y., and, Finn, R. S., (2012) Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br. J. Cancer 106, 6-13.
81. Nahta, R., and, Esteva, F. J., (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8, 215.
82. Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., et al. (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770.
83. Ainsworth, C., (2011) Networking for new drugs. Nat Med. 17, 1166-1168.